An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) will be participating in the 42nd Annual J.P. Morgan Healthcare Conference. CEO Brian McKelligon is scheduled to present on January 10th, 2024. A live and archived webcast of the event will be available on the Akoya website.
Positive
None.
Negative
None.
MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42nd Annual J.P. Morgan Healthcare Conference.
Brian McKelligon, CEO, is scheduled to present on Wednesday, January 10th, 2024 at 3:45 p.m. PT.
A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.
About Akoya Biosciences As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact: Priyam Shah Sr. Director, Investor Relations Akoya Biosciences, Inc. investors@akoyabio.com
akoya biosciences is developing a novel high-parameter tissue analysis platform, at an order of magnitude beyond what is currently possible. our codex (tm) (co-detection by indexing) system enables deep proteomic profiling...all on your existing microscope. if you are a scientist or software engineer interested in revolutionizing the science of imaging, then akoya is the place for you. contact is at info@akoyabio.com.